ANXA1 and melanoma: Moreover, the treatment of the melanoma cells with the mimetic AnxA1 N-terminal peptide Ac2–26 stimulated the invasiveness by increasing MMP-2 expression, depending on FPR/MAPK/STAT3 activation pathways [46,47,48].